e-learning
resources
Berlin 2001
Sunday 23.09.2001
Asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cost consequences of tiotropium plus existing therapy
versus
existing therapy alone following one year of treatment in patients with COPD
M. Friedman, T. Bell, S. S. Menjoge, S. Anton, P. Koch (New Orleans, Research Triangle Park, Ridgefield, United States Of America)
Source:
Annual Congress 2001 - Asthma
Session:
Asthma
Session type:
Oral Presentation
Number:
139
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Friedman, T. Bell, S. S. Menjoge, S. Anton, P. Koch (New Orleans, Research Triangle Park, Ridgefield, United States Of America). Cost consequences of tiotropium plus existing therapy
versus
existing therapy alone following one year of treatment in patients with COPD. Eur Respir J 2001; 16: Suppl. 31, 139
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002
Cost burden in COPD patients initiating ICS vs. non-ICS maintenance regimens
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021
Cost analysis for patients with severe asthma receiving omalizumab treatment
Source: International Congress 2019 – Clinical aspects of airway diseases
Year: 2019
Long-term treatment with fluticasone propionate/formoterol fumarate (FLUT/FORM) combination therapy is well-tolerated and provides sustained effectiveness in paediatric patients with asthma
Source: Annual Congress 2011 - Treating childhood asthma
Year: 2011
Resource utilization and economic impact of switching uncontrolled asthma and exacerbating COPD patients on monotherapy to fixed dose combination treatment in Germany
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012
Overall and cardiovascular safety of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in patients with COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 314s
Year: 2006
The efficacy of salmeterol/fluticasone (SF) for 6-month therapy in severe COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 30s
Year: 2006
Budesonide/formoterol for maintenance and relief
vs.
higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
Clinical and economic impact of an improvement in adherence based on specific attributes of single-inhaler triple therapies in COPD patients
Source: International Congress 2019 – Inhalers: adherence and preference
Year: 2019
Impact of once-daily single inhaler triple therapy on healthcare resource utilization and associated costs in COPD patients in Spain
Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs
Year: 2018
Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Are patients with COPD more adherent to single-inhaler compared with multiple-inhaler triple therapy in a real-world UK primary care treated population?
Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data
Year: 2021
Efficacy and safety of long-term therapy with Salamol combined with Beclason
versus
Salamol only in patients with mild persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002
Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009
Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 1237-1242
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept